Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
N Reesink-Peters1, B M T Hougardy, F A J van den Heuvel
1Department of Gynecologic Oncology, University Hospital Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands.
Objective:
Increasing imbalance between proliferation and apoptosis is important in cervical carcinogenesis. The death ligands FasL and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induce apoptosis by binding to their cognate cell-surface death receptors Fas or death receptor (DR) 4 and DR5. This study aims to examine if changes in death ligand and death receptor expression during different stages of cervical carcinogenesis are related to an imbalance between proliferation and apoptosis.
Methods:
The immunohistochemical expression and localization of Fas/FasL and DR4/DR5/TRAIL were assessed in 11 normal cervices, 15 cervical intraepithelial neoplasia (CIN) grade I, 15 CIN II, 13 CIN III, and 25 (microinvasive) squamous cell cervical cancers. The number of apoptotic cells was determined by morphological criteria and the number of proliferating cells by counting Ki-67-positive cells.
Results:
A marked increase in proliferation as well as apoptosis percentage was found with increasing severity of neoplasia. In normal cervix and CIN I samples, FasL, DR4, DR5, and TRAIL staining was mainly observed in the basal/parabasal layer, whereas Fas staining was localized in the superficial, more differentiated epithelial layer. Frequency of Fas-positive staining decreased with increasing severity of CIN. In contrast, homogeneous FasL, DR4, DR5, and TRAIL expression throughout the lesions was more frequently observed in CIN III and cervical cancer. FasL, DR4, DR5, and TRAIL staining patterns were correlated, although TRAIL expression was more intense in low-grade lesions. No association was found between death receptor or ligand expression with the percentage of apoptosis or proliferation.
Conclusion:
The loss of Fas and the deregulation of FasL, DR4, DR5, and TRAIL in the CIN-cervical cancer sequence suggest a possible functional role of these death ligands and receptors during cervical carcinogenesis. The frequent expression of DR4 and DR5 presents these receptors as promising targets for innovative therapy modalities in cervical cancer.
Insights
Changes in Fas and TRAIL pathways are linked to cervical cancer development. Deregulation of these death ligands and receptors suggests a role in carcinogenesis, with DR4 and DR5 offering potential therapeutic targets.
Area of Science:
- Oncology
- Cell Biology
- Molecular Pathology
Background:
- Cervical carcinogenesis involves an imbalance between cell proliferation and apoptosis.
- Death ligands (FasL, TRAIL) and their receptors (Fas, DR4, DR5) mediate apoptosis.
- Understanding their expression changes is crucial for cervical cancer research.
Purpose of the Study:
- To investigate the expression of Fas/FasL and DR4/DR5/TRAIL during cervical carcinogenesis.
- To correlate these changes with proliferation and apoptosis.
- To identify potential therapeutic targets in cervical cancer.
Main Methods:
- Immunohistochemistry used to assess Fas/FasL and DR4/DR5/TRAIL expression in normal cervix, CIN, and cervical cancer tissues.
- Proliferation assessed by Ki-67 staining.
- Apoptosis quantified morphologically.
Main Results:
- Increased proliferation and apoptosis observed with increasing severity of cervical neoplasia.
- Fas expression decreased, while FasL, DR4, DR5, and TRAIL expression became more widespread in higher-grade lesions.
- No direct correlation found between death receptor/ligand expression and apoptosis or proliferation rates.
Conclusions:
- Loss of Fas and altered expression of FasL, DR4, DR5, and TRAIL suggest a role in cervical carcinogenesis.
- DR4 and DR5 represent promising therapeutic targets for cervical cancer treatment.
Related Concept Videos
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
02:38Mitogens and the Cell Cycle